Platelet Function in Dogs Treated for Lymphoma and Hemangiosarcoma and Supplemented with Dietaryn‐3 Fatty Acids

Abstract

A prospective randomized, double‐blind clinical trial was performed to test the hypothesis that dogs with malignancies that are supplemented withn‐3 fatty acids do not have clinical or laboratory evidence of coagulation disorders or altered platelet function when compared with unsupplemented dogs with similar malignancies. Thirteen dogs with hemangiosarcoma and 66 dogs with lymphoma were evaluated. Coagulation status of the dogs with lymphoma and hemangiosarcoma was evaluated with prothombin time, partial thromboplastin time, platelet count, and in vitro platelet aggregometry using the whole‐blood method. These tests were performed at 5 time points: before beginning the diet (week 0), at weeks 3, 15, and 21, and at 1 year or when progressive disease was evident. Alterations in platelet function in dogs receiving a diet supplemented with dietaryn‐3 fatty acids were not identified when compared to dogs fed a control diet. Dietaryn‐3 fatty acid supplementation using this dosage and ratio in dogs with lymphoma or hemangiosarcoma did not induce clinically significant hemorrhage in these animals. Therefore, supplementation withn‐3 fatty acids did not result in clinical or laboratory evidence relating to uncontrolled hemorrhage in these dogs.